Conference on Retroviruses and Opportunistic Infections
Early ART in Infants: Longitudinal Results and the Mississippi Baby
These presentations provided a wealth of data suggesting that very early treatment of HIV may help control viremia and achieve remission over time in pediatric patients.
Cardiac Comorbidities in HIV: Role of Depression, Visceral Fat, Sex, and Exposure to ART
Here: 4 subgroups of HIV patients whose cardiovascular health might benefit from your targeted intervention.
Poster Presentations at CROI 2014: A Primary Care Perspective
Useful details here about HIV and age-related issues, sexual dysfunction, heart disease, and end-organ damage.
A Battle Plan for Surviving CROI and Other Week-Long Meetings
These suggestions will enhance your enjoyment of long meetings and will have your colleagues remarking on what a jolly, friendly person you really are. Ignore the advice at your own peril.
CROI 2014: The Good, The Bad, and The Ugly
The good: this premier HIV conference offers a banquet of exceptional material. The bad: the expense and the grind of covering a meeting this rich—and lengthy.
Antiretroviral Combinations Compared: Are We Closer to Declaring a Winner?
Two studies demonstrate that raltegravir is an extremely well-tolerated and potent component of a combination antiretroviral regimen.
Neuro-HIV: Replication of HIV in Adults in the CNS Early After Infection
Replication of HIV within the CNS continues to be a hot topic, because it represents a viral reservoir that can complicate treatment, as well as control and prevention efforts.
HIV Transmission Networks
“Super-spreaders” continue to play a major role in various epidemics, including tuberculosis and HIV infection.
Targeting Prevention of HIV-1 Transmission
Preliminary study results confirm that patient education and targeting those in higher-risk populations or who engage in high-risk behaviors continue to be important in preventing HIV transmission. Four specific recommendations here.
Making Sense Out of a Plethora of Hepatitis C Clinical Trials Results
It is quite likely that we have entered a new era of treatment for individuals either mono-infected with HCV or co-infected with HCV/HIV. Details here.